EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticus

Nicole F Maranchick iD, Katharina M Busl iD, Ralisa Pop, Camila Guerrero Miranda, Hector David Meza Comparan, Luciola Martins Frota, Lawrence J Hirsch, Stephan Eisenschenk, Charles A Peloquin iD, Carolina B Maciel

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026

DOI: 10.1002/phar.70198 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Verfasst von Nicole F Maranchick und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research, Infectious Disease Pharmacokinetics Lab, College of Pharmacy and Emerging Pathogens Institu…. Hauptthemen laut MEDLINE: Anticonvulsants, Status Epilepticus, Vigabatrin. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association Innovative Award 20IPA35380013; Wayne Densch Epilepsy Research Fund, UF Health Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Post‐anoxic status epilepticus (PASE) is a frequent neurologic complication following hypoxic–ischemic brain injury in cardiac arrest survivors, for which no definitive treatment exists. Early γ‐Aminobutyric Acid (GABA) augmentation using vigabatrin, a GABA‐transaminase inhibitor, has been proposed; however, its pharmacokinetics (PK) in this critically ill population are unknown. In this ancillary study of VIGAB‐STAT, an open‐label feasibility trial of loading dose vigabatrin via enteral tube, we evaluated vigabatrin PK. Materials and Methods Comatose adults with electrographic status epilepticus following return of spontaneous circulation received a loading dose of vigabatrin determined by renal function (creatinine clearance (CrCl) ≥ 50 mL/min, 4500 mg; CrCl 30–50 mL/min, 2250 mg; CrCl < 30 mL/min, 1125 mg). Pharmacokinetic sampling occurred at 0 (pre‐dose), 0.5, 1, 2, 3, 6, 12, 24, 48, 72, and 168‐h post‐dose, and plasma concentrations were quantified using liquid chromatography tandem mass spectrometry. PK parameters were estimated using non‐compartmental analysis.

Results

Six participants contributed 56 plasma samples. The median (range) age was 62 years (22–68), weight 80.9 kg (57.6–139.9), and four (66.7%) participants were male. Loading doses were evenly distributed: 4500 mg ( n = 2), 2250 mg ( n = 2), and 1125 mg ( n = 2). Time to maximum concentration, maximum concentration, area under the concentration time curve from 0 to 24 h, area under the concentration time curve from 0 to infinity and half‐life median (range) values were 2 h (1–3), 38.1 mg/L (16.9–91.8), 431.2 mg*h/L (254.6–979.3), 679.3 mg*h/L (340.3–1156.8), and 16.2 h (9.4–23.9), respectively.

Conclusions

This pioneer vigabatrin PK study in critically ill participants with PASE demonstrated absorption regardless of challenges such as enteral delivery type, co‐administration of gastric pH modulators, vasopressors, and anesthetics. Notably, prolonged elimination half‐lives and increased exposures were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsStatus EpilepticusVigabatrinAdultAgedFemaleHumansMaleMiddle AgedComaIntubation, Gastrointestinal

Stichwörter der Autor:innen

GABAcardiac arrestheart arrestpharmacokineticspost‐anoxic status epilepticusvigabatrin

Substanzen

AnticonvulsantsVigabatrin

Autor:innen und Institutionen

  • Department of Pharmacotherapy and Translational Research, Infectious Disease Pharmacokinetics Lab, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.
  • Department of Neurology, Division of Neurocritical Care, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Department of Neurology, Malcolm Randall VA Medical Center, Gainesville, Florida, USA.
  • National Tele-EEG Program, VA Boston Healthcare System, Boston, Massachusetts, USA.

ORCID-Profile: Nicole F Maranchick, Katharina M Busl, Charles A Peloquin

Förderung

  • American Heart Association Innovative Award 20IPA35380013; Wayne Densch Epilepsy Research Fund, UF Health Foundation

Zitieren

APA

Maranchick, N. F., Busl, K. M., Pop, R., Miranda, C. G., Comparan, H. D. M., Frota, L. M., Hirsch, L. J., Eisenschenk, S., Peloquin, C. A., & Maciel, C. B. (2026). Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70198

Vancouver

Maranchick NF, Busl KM, Pop R, Miranda CG, Comparan HDM, Frota LM, et al. Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70198

BibTeX
@article{Maranchick2026,
  author = {Maranchick, Nicole F and Busl, Katharina M and Pop, Ralisa and Miranda, Camila Guerrero and Comparan, Hector David Meza and Frota, Luciola Martins and Hirsch, Lawrence J and Eisenschenk, Stephan and Peloquin, Charles A and Maciel, Carolina B},
  title = {Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticus},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  doi = {10.1002/phar.70198}
}
Kostenlos starten →